Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial

Low-grade intermediate-risk nonmuscle-invasive bladder cancer (LG IR NMIBC) is a recurrent disease, thus requiring repeated transurethral resection of bladder tumor under general anesthesia. We evaluated the efficacy and safety of UGN-102, a mitomycin-containing reverse thermal gel, as a primary che...

Descripción completa

Detalles Bibliográficos
Autores principales: Chevli, K. Kent, Shore, Neal D., Trainer, Andrew, Smith, Angela B., Saltzstein, Daniel, Ehrlich, Yaron, Raman, Jay D., Friedman, Boris, D’Anna, Richard, Morris, David, Hu, Brian, Tyson, Mark, Sankin, Alexander, Kates, Max, Linehan, Jennifer, Scherr, Douglas, Kester, Steven, Verni, Michael, Chamie, Karim, Karsh, Lawrence, Cinman, Arnold, Meads, Andrew, Lahiri, Soumi, Malinowski, Madlen, Gabai, Nimrod, Raju, Sunil, Schoenberg, Mark, Seltzer, Elyse, Huang, William C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2022
Materias:
Adult Urology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667793/
https://www.ncbi.nlm.nih.gov/pubmed/34433303
http://dx.doi.org/10.1097/JU.0000000000002186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667793/
https://www.ncbi.nlm.nih.gov/pubmed/34433303
http://dx.doi.org/10.1097/JU.0000000000002186

Ejemplares similares